A Fatal Case of Bictegravir-Induced Fulminant Hepatic Failure.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Works matching IS 11732563 AND DT 2023 AND VI 43 AND IP 3
Results: 6
1
2
Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 3, p. 167, doi. 10.1007/s40261-023-01247-w
- By:
- Publication type:
- Article
3
A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 3, p. 197, doi. 10.1007/s40261-023-01248-9
- By:
- Publication type:
- Article
4
Evaluation of Cardiac Adverse Events with Nivolumab Using a Japanese Real-World Database.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 3, p. 177, doi. 10.1007/s40261-023-01246-x
- By:
- Publication type:
- Article
5
Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 3, p. 185, doi. 10.1007/s40261-022-01240-9
- By:
- Publication type:
- Article
6
A Single- and Multiple-Dose Pharmacokinetic Study of Oral Perampanel in Healthy Chinese Subjects.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 3, p. 155, doi. 10.1007/s40261-022-01241-8
- By:
- Publication type:
- Article